MVA-HPV16E6/E7-IL2 vaccine TG4001

{
  "id": "MLC-T-ONC-015383",
  "term": "MVA-HPV16E6/E7-IL2 vaccine TG4001",
  "field": "Oncology and biomedicine",
  "definition": "A cancer vaccine comprised of a modified, replication-defective, vaccinia virus Ankara (MVA) strain encoding the tumor-associated antigens (TAAs) human papillomavirus type 16 (HPV16) subtypes E6 and E7, and human interleukin-2 (IL-2), with potential immunostimulating and antineoplastic activities. Vaccination with MVA-HPV16E6/E7-IL2 vaccine TG4001 stimulates the host immune system to mount a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing HPV16 E6 and E7, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against HPV16 E6- and E7-expressing tumor cells.",
  "synonyms": [
    "recombinant vaccinia viral vector RO5217790",
    "MVA-HPV-IL2",
    "MVA-HPV16E6/E7-IL2",
    "HPV16 E6/E7-encoding MVA vaccine TG4001"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/mva-hpv16e6-e7-il2-vaccine-tg4001/"
}